Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Other Non-Current Liabilities came in at $400000.0 in Q1 2026, down 90.98% year-on-year from $4.4 million in Q1 2025, and down 90.98% on a QoQ basis from $4.4 million in Q1 2025.
Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 2 years of Other Non-Current Liabilities data on file, last reported at $400000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2025 | 4.44 Mn |